The investigative process for new drugs

Area of Science:

• Pharmaceutical Sciences
• Drug Development
• Regulatory Science

Background:

• New drug development involves distinct preclinical and clinical research stages.
• Clinical development is structured into three phases under an Investigational New Drug (IND) application.
• Regulatory bodies like the FDA oversee the drug approval process.

Purpose of the Study:

• To outline the sequential phases of drug development.
• To define the objectives of each clinical trial phase (I, II, III).
• To discuss the requirements for marketing approval and post-marketing surveillance.

Main Methods:

• Preclinical studies to assess initial drug properties.
• Phase I trials focus on initial drug safety and dosage in a small group.
• Phase II trials evaluate drug efficacy and side effects in a larger patient cohort.
• Phase III trials assess long-term safety and efficacy in extensive patient populations.
• New Drug Application (NDA) submission for regulatory review.

Main Results:

• Successful completion of all study phases is necessary for drug approval.
• Demonstration of drug safety and efficacy is paramount for regulatory acceptance.
• Post-marketing surveillance provides ongoing evaluation of drug performance.

Conclusions:

• The phases for demonstrating drug safety and efficacy are well-defined.
• Optimal methodologies for meeting these requirements allow for interpretation by sponsors and reviewers.
• While guidelines are crucial, expert judgment remains essential throughout the drug development and review process.